Related Experiment Video
Updated: Aug 30, 2026
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Antidepressant drug treatment induces Arc gene expression in the rat brain
Q Pei1, T S C Zetterström, M Sprakes
1University Department of Pharmacology, Mansfield Road, Oxford, OX1 3QT, UK. qi.pei@pharm.ox.ac.uk
Abstract:
The mechanism underlying the therapeutic effect of antidepressants is not known but neuroadaptive processes akin to long-term potentiation have been postulated. Arc (Activity-regulated, cytoskeletal-associated protein) is an effector immediate early gene implicated in LTP and other forms of neuroplasticity. Recent data show that Arc expression is regulated by brain 5-hydroxytryptamine neurones, a target of many antidepressants. Here in situ hybridisation and immunohistochemistry were used to examine whether Arc expression in rat brain is altered by antidepressant drug treatment. Repeated administration of the monoamine reuptake inhibitors paroxetine, venlafaxine or desipramine induced region-specific increases in Arc mRNA. These increases were greatest in regions of the cortex (frontal and parietal cortex) and hippocampus (CA1 layer) and absent in the caudate putamen. Repeated treatment with the monoamine oxidase inhibitor, tranylcypromine, increased Arc mRNA in a similar fashion to the monoamine reuptake inhibitors. The antidepressant drugs also increased the number of Arc-immunoreactive cells in the parietal cortex. Acute antidepressant injection, and repeated administration of the antipsychotic drug chlorpromazine, produced either limited or no changes in Arc mRNA. The data suggest that chronic treatment with antidepressant drugs induces Arc gene expression in specific regions across the rat forebrain. Up-regulation of Arc expression may be part of the process by which antidepressant drugs achieve long-term changes in synaptic function in the brain.
Insights
Antidepressant treatment increases the expression of the Activity-regulated, cytoskeletal-associated protein (Arc) gene in specific brain regions. This neuroadaptive change in Arc may contribute to the long-term therapeutic effects of these drugs.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- The therapeutic mechanisms of antidepressants remain largely unknown.
- Neuroadaptive processes, such as long-term potentiation (LTP), are implicated in antidepressant action.
- Activity-regulated, cytoskeletal-associated protein (Arc) is an immediate early gene crucial for neuroplasticity and LTP.
Purpose of the Study:
- To investigate whether chronic antidepressant drug administration alters Arc gene expression in the rat brain.
- To determine if Arc expression changes are specific to antidepressant treatments and brain regions.
Main Methods:
- Utilized in situ hybridization and immunohistochemistry techniques in rat models.
- Examined the effects of repeated administration of various antidepressant classes (monoamine reuptake inhibitors, monoamine oxidase inhibitors).
- Compared effects with acute antidepressant administration and a non-antidepressant antipsychotic drug.
Main Results:
- Repeated administration of paroxetine, venlafaxine, and desipramine significantly increased Arc mRNA levels, particularly in the frontal cortex, parietal cortex, and hippocampus (CA1).
- The monoamine oxidase inhibitor tranylcypromine demonstrated similar region-specific increases in Arc mRNA.
- Antidepressant treatments also elevated the number of Arc-immunoreactive cells in the parietal cortex.
- Acute antidepressant treatment and chronic chlorpromazine administration showed minimal or no significant changes in Arc mRNA.
Conclusions:
- Chronic antidepressant treatment, including both monoamine reuptake inhibitors and monoamine oxidase inhibitors, induces region-specific upregulation of Arc gene expression in the rat forebrain.
- The observed increase in Arc expression suggests it may be a key molecular component involved in the long-term synaptic adaptations underlying antidepressant efficacy.
